ArticleESMO gastrointestinal oncology2026
Real-world insights into young-onset gastroesophageal adenocarcinoma: an all-Ireland population-based cancer registry analysis.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Data resource profile: National Cancer Registry Ireland.ESMO real world data and digital oncology · 2026Article
- Early onset gastrointestinal cancers - a needs analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Population-based studies report a rising incidence of young-onset (YO) oesophageal and gastric cancer. We examined clinicopathological features, treatment, and outcomes in YO (18-50 years), midlife-onset (MO, 50-70 years), and late-onset (LO, >70 years) oesophageal and gastric adenocarcinoma. Methods: Population-based data were collected from the National Cancer Registry Ireland (NCRI) and Northern Ireland Cancer Registry (NICR). Incidence trends were determined using Joinpoint regression. Kaplan-Meier curves, log-rank tests, and multivariable Cox regression were used to assess survival differences. Multivariable Cox regression was adjusted for key clinical covariates, and excluded patients with missing covariates. Results: We analysed 21 706 patients diagnosed with oesophageal or gastric adenocarcinoma from 1999 to 2022. YO gastric tumours were more diffuse (YO 26.6% versus MO 13.8% versus LO 10.4%, Conclusion: Oesophageal adenocarcinoma incidence is rising across all age groups, while gastric adenocarcinoma incidence was stable in the YO population and declining in older adults. Despite more advanced and aggressive disease at presentation, YO patients had better overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.